A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Article Multidisciplinary Sciences

Prevalence and impact of visual aura in migraine and probable migraine: a population study

Kyung Min Kim et al.

Summary: The prevalence of visual aura is similar in patients with migraine and probable migraine, but in the presence of visual aura, patients experience higher headache frequency, more severe cutaneous allodynia, and greater disability.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Article Anesthesiology

Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019

Saeid Safiri et al.

Summary: The Global Burden of Disease Study 2019 revealed an increase in the burden of migraine from 1990 to 2019, with significant intercountry differences. Migraine prevalence was higher in females and decreased with age after the 40 to 44 age group. Enhanced migraine care is necessary to increase awareness of risk factors and treatment strategies, particularly among young adults and middle-aged women, as well as to gather more data on migraines.

PAIN (2022)

添加到收藏夹

Correction Clinical Neurology

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)

Ali H. Mokdad

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

Fenne Vandervorst et al.

Summary: The new class of migraine preventive drugs, monoclonal antibodies targeting the CGRP pathway, demonstrates efficacy comparable to or higher than currently used preventive drugs, supported by robust evidence from large randomized clinical trials. Their excellent tolerability and emerging long-term safety data suggest an unprecedented efficacy-over-adverse-effect profile, adding value to migraine prevention.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study

Shuu-Jiun Wang et al.

Summary: The study demonstrated the efficacy and safety of erenumab in adults with episodic migraine from Asia, the Middle East, and Latin America. Both doses of erenumab showed significant advantages in reducing migraine days and acute migraine-specific medication treatment days. This extends evidence of erenumab's effectiveness and safety to under-represented patient populations in previous trials.

CEPHALALGIA (2021)

添加到收藏夹

Article Clinical Neurology

Delivery of care for migraine in the Asian Oceanian region: A cross-sectional study

Artemio Roxas et al.

Summary: The study revealed the lack of clinical guidelines, subspecialty training, dedicated headache clinics, and patient advocacy organizations for headache care in the participating countries. Most countries offer acute and prophylactic medications for migraine treatment, but approved non-pharmacologic devices are scarce. The recommendations from the 2011 Atlas of Headache Disorders have yet to be fully implemented.

CEPHALALGIA (2021)

添加到收藏夹

Article Clinical Neurology

Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency

Ryotaro Ishii et al.

Summary: The study findings suggest that using a 15 headache day/month threshold to distinguish episodic and chronic migraine does not fully capture the burden of illness or reflect the treatment needs of patients, which has important implications for future refinements in migraine classification.

HEADACHE (2021)

添加到收藏夹

Editorial Material Clinical Neurology